NMR-based design and evaluation of novel bidentate inhibitors of the protein tyrosine phosphatase YopH

Chemical Biology and Drug Design

Volumn 76, Issue 1, 2010, Pages 10-16

  Leone, Marilisa ^a,b   Barile, Elisa ^a   Vazquez, Jesus ^a   Mei, Angel ^a   Guiney, Donald ^c   Dahl, Russel ^a   Pellecchia, Maurizio ^a  

^a BURNHAM INSTITUTE   (United States)

^b CNR   (Italy)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

NMR screening; Protein tyrosine phosphatase; Spin label; Yersinia; YopH

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; BIDENTATE DERIVATIVE; FURANYL SALICYLATE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN YOPH; UNCLASSIFIED DRUG; MOLECULAR LIBRARY; OUTER MEMBRANE PROTEIN; YOPH PROTEIN, YERSINIA;

ANTIBACTERIAL ACTIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR PROBE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SPIN LABELING; STRUCTURE ACTIVITY RELATION; YERSINIA PESTIS; YERSINIA PSEUDOTUBERCULOSIS; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HELA CELL LINE; METABOLISM; MOLECULAR LIBRARY; NUCLEAR MAGNETIC RESONANCE; PHARMACOLOGY; PROCEDURES; YERSINIA; YERSINIA INFECTIONS;

BACTERIAL OUTER MEMBRANE PROTEINS; DRUG DESIGN; HELA CELLS; HUMANS; MODELS, MOLECULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN TYROSINE PHOSPHATASES; SMALL MOLECULE LIBRARIES; YERSINIA; YERSINIA INFECTIONS;

YERSINIA; YERSINIA PESTIS; YERSINIA PSEUDOTUBERCULOSIS;

EID: 77952976580     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.00982.x     Document Type: Article

References (35)

1. Persson C., Nordfelth R., Holmstrom A., Hakansson S., Rosqvist R., Wolf-Watz H. (1995) Cell-surface-bound Yersinia translocate the protein tyrosine phosphatase YopH by a polarized mechanism into the target cell. Mol Microbiol 18 : 135 150.
2. Cheng L.W., Schneewind O. (2000) Yersinia enterocolitica TyeA, an intracellular regulator of the type III machinery, is required for specific targeting of YopE, YopH, YopM, and YopN into the cytosol of eukaryotic cells. J Bacteriol 182 : 3183 3190.
3. Cornelis G.R. (2000) Type III secretion: a bacterial device for close combat with cells of their eukaryotic host. Philos Trans R Soc Lond B Biol Sci 355 : 681 693.
4. Cornelis G.R. (2000) Molecular and cell biology aspects of plague. Proc Natl Acad Sci USA 97 : 8778 8783.
5. Phan J., Lee K., Cherry S., Tropea J.E., Burke T.R. Jr., Waugh D.S. (2003) High-resolution structure of the Yersinia pestis protein tyrosine phosphatase YopH in complex with a phosphotyrosyl mimetic-containing hexapeptide. Biochemistry 42 : 13113 13121.
6. Black D.S., Marie-Cardine A., Schraven B., Bliska J.B. (2000) The Yersinia tyrosine phosphatase YopH targets a novel adhesion-regulated signalling complex in macrophages. Cell Microbiol 2 : 401 414.
7. Black D.S., Montagna L.G., Zitsmann S., Bliska J.B. (1998) Identification of an amino-terminal substrate-binding domain in the Yersinia tyrosine phosphatase that is required for efficient recognition of focal adhesion targets. Mol Microbiol 29 : 1263 1274.
8. Khandelwal P., Keliikuli K., Smith C.L., Saper M.A., Zuiderweg E.R. (2002) Solution structure and phosphopeptide binding to the N-terminal domain of Yersinia YopH: comparison with a crystal structure. Biochemistry 41 : 11425 11437.
9. Guan K.L., Dixon J.E. (1990) Protein tyrosine phosphatase activity of an essential virulence determinant in Yersinia. Science 249 : 553 556.
10. Bubeck S.S., Dube P.H. (2007) Yersinia pestis CO92 delta yopH is a potent live, attenuated plague vaccine. Clin Vaccine Immunol 14 : 1235 1238.
11. Vazquez J., Tautz L., Ryan J.J., Vuori K., Mustelin T., Pellecchia M. (2007) Development of molecular probes for second-site screening and design of protein tyrosine phosphatase inhibitors. J Med Chem 50 : 2137 2143.
12. Jahnke W., Rudisser S., Zurini M. (2001) Spin label enhanced NMR screening. J Am Chem Soc 123 : 3149 3150.
13. Jahnke W., Florsheimer A., Blommers M.J., Paris C.G., Heim J., Nalin C.M., Perez L.B. (2003) Second-site NMR screening and linker design. Curr Top Med Chem 3 : 69 80.
14. Jahnke W. (2002) Spin labels as a tool to identify and characterize protein-ligand interactions by NMR spectroscopy. Chembiochem 3 : 167 173.
15. Vazquez J., De S.K., Chen L.H., Riel-Mehan M., Emdadi A., Cellitti J. et al. (2008) Development of paramagnetic probes for molecular recognition studies in protein kinases. J Med Chem 51 : 3460 3465.
16. Black E., Breed J., Breeze A.L., Embrey K., Garcia R., Gero T.W. et al. (2005) Structure-based design of protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett 15 : 2503 2507.
17. Tautz L., Bruckner S., Sareth S., Alonso A., Bogetz J., Bottini N. et al. (2005) Inhibition of Yersinia tyrosine phosphatase by furanyl salicylate compounds. J Biol Chem 280 : 9400 9408.
18. Tautz L., Mustelin T. (2007) Strategies for developing protein tyrosine phosphatase inhibitors. Methods 42 : 250 260. (Pubitemid 46783589)
19. Khandelwal P., Keliikuli K., Smit C.L., Saper M.A., Zuiderweg E.R. (2001) 1H, 15N and 13C assignments of the N-terminal domain of Yersinia outer protein H in its apo form and in complex with a phosphotyrosine peptide. J Biomol NMR 21 : 69 70.
20. Alonso A., Bottini N., Bruckner S., Rahmouni S., Williams S., Schoenberger S.P. et al. (2004) Lck dephosphorylation at Tyr-394 and inhibition of T cell antigen receptor signaling by Yersinia phosphatase YopH. J Biol Chem 279 : 4922 4928.
21. Wu S., Vossius S., Rahmouni S., Miletic A.V., Vang T., Vazquez-Rodriguez J. et al. (2009) Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells. J Med Chem 52 : 6716 6723.
22. Teschner M., Henn C., Vollhardt H., Reiling S., Brickmann J. (1994) Texture mapping: a new tool for molecular graphics. J Mol Graph 12 : 98 105.
23. Eldridge M.D., Murray C.W., Auton T.R., Paolini G.V., Mee R.P. (1997) Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 11 : 425 445.
24. Wu B., Rega M.F., Wei J., Yuan H., Dahl R., Zhang Z. et al. (2009) Discovery and binding studies on a series of novel Pin1 ligands. Chem Biol Drug Des 73 : 369 379.
25. Browne S.H., Lesnick M.L., Guiney D.G. (2002) Genetic requirements for salmonella-induced cytopathology in human monocyte-derived macrophages. Infect Immun 70 : 7126 7135.
26. Becattini B., Culmsee C., Leone M., Zhai D., Zhang X., Crowell K.J. et al. (2006) Structure-activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid. Proc Natl Acad Sci USA 103 : 12602 12606.
27. Becattini B., Pellecchia M. (2006) SAR by ILOEs: an NMR-based approach to reverse chemical genetics. Chemistry 12 : 2658 2662.
28. Pellecchia M., Becattini B., Crowell K.J., Fattorusso R., Forino M., Fragai M. et al. (2004) NMR-based techniques in the hit identification and optimisation processes. Expert Opin Ther Targets 8 : 597 611.
29. Pellecchia M. (2005) Solution nuclear magnetic resonance spectroscopy techniques for probing intermolecular interactions. Chem Biol 12 : 961 971.
30. Bartels C., Xia T.H., Billeter M., Güntert P., Wüthrich K. (1995) The program XEASY for computer-supported NMR spectral analysis of biological macromolecules. J Biomol NMR 5 : 1 10.
31. Pellecchia M., Bertini I., Cowburn D., Dalvit C., Giralt E., Jahnke W. et al. (2008) Perspectives on NMR in drug discovery: a technique comes of age. Nat Rev Drug Discov 7 : 738 745.
32. Hajduk P.J., Dinges J., Miknis G.F., Merlock M., Middleton T., Kempf D.J. et al. (1997) NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. J Med Chem 40 : 3144 3150.
33. Hajduk P.J. (2006) SAR by NMR: putting the pieces together. Mol Interv 6 : 266 272.
34. Tautz L., Pellecchia M., Mustelin T. (2006) Targeting the PTPome in human disease. Expert Opin Ther Targets 10 : 157 177.
35. Pellecchia M., Sem D.S., Wuthrich K. (2002) NMR in drug discovery. Nat Rev Drug Discov 1 : 211 219.